Search Videos by Topic or Participant
Browse by Series:

The Role of Biomarkers in Neuroendocrine Tumors

Panelists: Matthew H. Kulke, MD, Dana-Farber; Pamela L. Kunz, MD, Stanford; Rodney F. Pommier, MD, OHSU; James C. Yao, MD, MD Anderson
Published: Thursday, Mar 21, 2013
For High-Definition, Click
Biomarkers can be used in a variety of ways for the management of patients with neuroendocrine tumors (NETs). James C. Yao, MD, notes that biomarkers may be used to aid in screening, diagnosis, prognosis, and predictively to select optimal treatments.

Varying levels of evidence and recommendations exist concerning biomarkers in NETs. Unfortunately, due to the intrinsic nature of the disease, a successful biomarker does not exist for screening patients, Yao regrets. However, to help diagnosis carcinoid tumors, Yao recommends the 5-HIAA test, which measures average serotonin levels over a 24 hour period. This marker is helpful but is not sufficient by itself to make a diagnosis.

Overall, selecting the most appropriate test should be tailored to the individual patient’s needs based on their symptoms. Yao and Rodney F. Pommier, MD, both agree that the markers examined should be selected very specifically on a patient-to-patient basis.
Slider Left
Slider Right
For High-Definition, Click
Biomarkers can be used in a variety of ways for the management of patients with neuroendocrine tumors (NETs). James C. Yao, MD, notes that biomarkers may be used to aid in screening, diagnosis, prognosis, and predictively to select optimal treatments.

Varying levels of evidence and recommendations exist concerning biomarkers in NETs. Unfortunately, due to the intrinsic nature of the disease, a successful biomarker does not exist for screening patients, Yao regrets. However, to help diagnosis carcinoid tumors, Yao recommends the 5-HIAA test, which measures average serotonin levels over a 24 hour period. This marker is helpful but is not sufficient by itself to make a diagnosis.

Overall, selecting the most appropriate test should be tailored to the individual patient’s needs based on their symptoms. Yao and Rodney F. Pommier, MD, both agree that the markers examined should be selected very specifically on a patient-to-patient basis.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x